The Microbial Regulation Spectrum of Metformin in Patients With Type 2 Diabetes: An Individual-Based Meta-Analysis of 1431 Participants
Authors' conclusion
Our analysis delivers more concrete evidence regarding the shifts in gut microbiota following metformin treatment, significantly enriching our understanding of the interplay between gut microbiome dynamics and the management of T2D.
Study context
- Population
- Patients with T2D, with and without metformin9 datasets
- Comparison
- Metformin-treated vs untreated T2D, and T2D vs healthy
- Outcome
- Gut microbiota changes with metformin
Methodological detailsraw sequence reads of 9 datasets reanalysed, Seven databases searched to October 30, 2024; 2 authors screened independently; standardized extraction form
- Raw sequence reads of 9 datasets reanalysed
- Seven databases searched to October 30, 2024; 2 authors screened independently; standardized extraction form
Pooled result
As reported in the abstract
- Metformin significantly increased Akkermansia and short-chain fatty acid (SCFA)-producing bacteria (Pseudobutyrivibrio, Oribacterium, Anaerotruncus)
- Metformin decreased pathogenic bacteria (Enterobacillus, Gemmobacter, Shinella, Klebsiella, Enterocloster)
- Bifidobacterium and Blautia increased in T2D, restored to near normal by metformin; alteration region-specific
Original publication
The Microbial Regulation Spectrum of Metformin in Patients With Type 2 Diabetes: An Individual-Based Meta-Analysis of 1431 Participants. J Clin Endocrinol Metab. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →